Health Care Renewal on the WSJ’s editorial on Nissen and Avandia:
So the Wall Street Journal’s new whirl has kept the Avandia spin cycle merrily revolving. This spin cycle continues to distract from what I think, in my humble opinion, are really the major questions.The first question is clinical: what are the benefits and harms of rosiglitazone as a treatment of Type 2 diabetes, and therefore for which patients under what circumstances should this drug be used?
The second question is about policy: what barriers, if any, have prevented physicians and patients from getting the best possible answer to the first question, and what can be done about them?
Related posts:
- Does Avandia cause heart attacks, and why the RECORD study is important
- Avandia and heart attacks
- Avandia: The RECORD study
- "Should I keep taking Avandia?"
- Avandia: "Watch the science, not the politics"
- Avandia, MI, and cardiac death
- Avandia and politics
KevinMD.com on Facebook
Comments on this entry are closed.